

Fifth Edition

Extended Stability *for Parenteral Drugs*

Caryn Dellamorte Bing
Anna Nowobilski-Vasilios

Donald J. Filibeck
Brenda L. Gray
J. Michael Hayes
Barbara Limburg-Mancini
Kevn M. McNamara
Diane Nitzki-George
Kevin L. Ross
Lisa Linn Siefert
Paula Zelle

American Society of Health-System Pharmacists®
Bethesda, Maryland

Any correspondence regarding this publication should be sent to the publisher, American Society of Health-System Pharmacists, 7272 Wisconsin Avenue, Bethesda, MD 20814, attention: Special Publishing.

The information presented herein reflects the opinions of the contributors and advisors. It should not be interpreted as an official policy of ASHP or as an endorsement of any product.

Because of ongoing research and improvements in technology, the information and its applications contained in this text are constantly evolving and are subject to the professional judgment and interpretation of the practitioner due to the uniqueness of a clinical situation. The editors, contributors, and ASHP have made reasonable efforts to ensure the accuracy and appropriateness of the information presented in this document. However, any user of this information is advised that the editors, contributors, and ASHP are not responsible for the continued currency of the information, for any errors or omissions, and/or for any consequences arising from the use of the information in the document in any and all practice settings. Any reader of this document is cautioned that ASHP makes no representation, guarantee, or warranty, express or implied, as to the accuracy and appropriateness of the information contained in this document and specifically disclaims any liability to any party for the accuracy and/or completeness of the material or for any damages arising out of the use or non-use of any of the information contained in this document.

Director, Acquisitions and Product Development: Jack Bruggeman
Editorial Project Manager: Ruth Bloom
Project Editor: Johnna Hershey
Cover and Page Design: David Wade

©2013, American Society of Health-System Pharmacists, Inc. All rights reserved.

No part of this publication may be reproduced or transmitted in any form or by any means, electronic or mechanical, including photocopying, microfilming, and recording, or by any information storage and retrieval system, without written permission from the American Society of Health-System Pharmacists.

ASHP ® is a service mark of the American Society of Health-System Pharmacists, Inc.; registered in the U.S. Patent and Trademark Office.

ISBN: 978-1-58528-3408

Dedication

EXTENDED STABILITY FOR PARENTERAL DRUGS

To the ever-growing network of colleagues who continue to inspire and encourage us:

It is impossible to recognize and thank you all appropriately for your continued support of this ongoing drug information project.

Acknowledgments

EXTENDED STABILITY FOR PARENTERAL DRUGS

As with the prior editions, the preparation of this updated reference was a team effort that would not have been possible without the exceptional group of capable writers and reviewers. They spent many hours on what some might consider minutia but this team considers essential. The editors appreciate the dedication and focus that these extremely talented and very busy professionals applied to this edition.

Contents

EXTENDED STABILITY FOR PARENTERAL DRUGS

Preface	ix	Ranitidine	38
About the Editors	xi	Selenium	39
Writers	xii	Trace Elements	39
How to Use This Reference	xiii	Vitamin A	40
Part I		Vitamin B1	42
Applying Stability Data in Patient Care	3	Vitamin B2	43
Introduction	3	Vitamin B3	44
Factors Affecting Extended Drug Stability	3	Vitamin B5	44
Preparation Sterility and Quality Assurance	4	Vitamin B6	45
Professional, Regulatory, and Accreditation		Vitamin B12.....	45
Expectations.....	5	Vitamin C.....	46
Commercial Products and Extemporaneous		Vitamin D.....	47
Compounding	7	Vitamin E	48
Infusate Properties	8	Vitamin K.....	49
Vascular Access Devices and Catheters		Zinc.....	49
Used in Medication Administration	9	References.....	50
Labeling Instructions.....	12		
Assigning Beyond-Use Dates.....	12	Part II	
Patient and Site-Specific Considerations	13	Drug Monographs	55
Considerations in Selecting Administration		Acetaminophen.....	57
Methods and Infusion Devices.....	15	Acyclovir Sodium.....	58
External Factors Affecting Stability	19	Aldesleukin	60
Ethanol and Antibiotic Locks	20	Amikacin Sulfate	61
Summary.....	20	Amiodarone Hydrochloride.....	63
References.....	20	Amphotericin B.....	64
Parenteral Nutrition	23	Amphotericin B Cholesteryl Sulfate	
Beyond-Use Dating of Parenteral Nutrition		Complex	66
Formulations	23	Amphotericin B Lipid Complex.....	67
Non-Formulation Factors Affecting PN		Amphotericin B Liposome	68
Stability.....	23	Ampicillin Sodium	69
Formulation Factors Affecting PN Stability.....	26	Ampicillin Sodium–Sulbactam Sodium.....	71
Commercial Products and Extemporaneous		Azithromycin	73
Compounding	29	Aztreonam.....	74
Professional, Regulatory, and Accreditation		Baclofen.....	76
Expectations and Guidance.....	29	Bevacizumab.....	78
Summary.....	30	Bleomycin Sulfate.....	79
Parenteral Nutrition Monographs.....	31	Bortezomib	80
Carnitine	31	Bumetanide	81
Chromium	31	Bupivacaine Hydrochloride	82
Cimetidine.....	32	Calcitriol	85
Copper	33	Carboplatin	86
Famotidine	34	Caspofungin Acetate.....	88
Folic Acid.....	35	Cefazolin Sodium	89
Heparin	36	Cefepime Hydrochloride	92
Iron.....	36	Cefotaxime Sodium.....	95
Manganese	37	Cefotetan Disodium	98

Contents

EXTENDED STABILITY FOR PARENTERAL DRUGS

Cefoxitin Sodium.....	100	Etoposide	175
Ceftaroline Fosamil	103	Etoposide Phosphate	177
Ceftazidime.....	104	Famotidine	178
Ceftriaxone Sodium	108	Fentanyl Citrate.....	179
Cefuroxime Sodium	112	Filgrastim.....	182
Chlorpromazine Hydrochloride	115	Floxuridine.....	183
Cidofovir	116	Fluconazole.....	184
Cimetidine Hydrochloride.....	117	Fludarabine Phosphate.....	186
Ciprofloxacin	119	Fluorouracil.....	187
Cisplatin	121	Foscarnet Sodium	190
Cladribine.....	123	Fosphenytoin Sodium	192
Clindamycin Phosphate.....	124	Furosemide	193
Clonidine Hydrochloride	126	Ganciclovir Sodium.....	194
Coagulation Factor VIIa Recombinant	128	Gemcitabine Hydrochloride	196
Coagulation Factor VIII	129	Gentamicin Sulfate.....	197
Coagulation Factor IX	133	Glycopyrrolate	199
Coagulation Factor XIII.....	135	Granisetron Hydrochloride.....	200
Colistimethate Sodium	136	Haloperidol Lactate.....	202
Co-Trimoxazole (Trimethoprim– Sulfamethoxazole)	137	Heparin Sodium.....	203
Cyclophosphamide	138	Hydralazine Hydrochloride	205
Cyclosporine	140	Hydrocortisone Sodium Succinate.....	206
Cytarabine	141	Hydromorphone Hydrochloride	207
Dacarbazine.....	143	Hydroxyzine Hydrochloride	209
Daclizumab.....	144	Ibuprofen	210
Daptomycin	145	Ifosfamide.....	211
Daunorubicin Hydrochloride (Daunomycin).....	147	Imipenem–Cilastatin Sodium.....	213
Deferoxamine Mesylate.....	148	Immune Globulin (Human)	215
Dexamethasone Sodium Phosphate.....	151	Infliximab	218
Dimenhydrinate	153	Interferon alfa-2b.....	219
Diphenhydramine.....	154	Irinotecan Hydrochloride.....	220
DOBUTamine Hydrochloride	155	Ketamine Hydrochloride	221
Docetaxel	156	Ketorolac Tromethamine	223
Dolasetron Mesylate.....	157	Leucovorin Calcium	225
DOPamine Hydrochloride	158	Levofloxacin	227
Doripenem	159	Linezolid	228
Doxorubicin Hydrochloride.....	161	Lorazepam.....	229
Doxycycline Hyclate.....	164	Meperidine Hydrochloride.....	231
Enoxaparin Sodium	166	Meropenem	233
Epirubicin Hydrochloride.....	167	Mesna	236
Epoetin Alfa	168	Methadone Hydrochloride.....	238
Epoprostenol Sodium.....	169	Methotrexate Sodium	239
Ertapenem	171	Methylprednisolone Sodium Succinate.....	241
Erythromycin Lactobionate.....	172	Metoclopramide Hydrochloride.....	243
Ethanol (Catheter Lock).....	174	Metronidazole, Metronidazole Hydrochloride	245
		Micafungin Sodium	247

Contents

EXTENDED STABILITY FOR PARENTERAL DRUGS

Midazolam.....	248	Sufentanil Citrate.....	290
Milrinone Lactate	250	Telavancin	292
Mitomycin	252	Thiotepa	293
Mitoxantrone Hydrochloride	253	Ticarcillin Disodium–Clavulanate Potassium.....	294
Morphine Sulfate.....	254	Tigecycline.....	296
Nafcillin Sodium.....	258	Tobramycin Sulfate	297
Octreotide Acetate.....	260	Tocilizumab	299
Ondansetron Hydrochloride.....	261	Topotecan Hydrochloride.....	300
Oprelvekin (Interleukin-11)	264	Trastuzumab	301
Oxacillin Sodium.....	265	Treprostinil	302
Oxaliplatin.....	268	Valproate Sodium.....	303
Oxytocin	269	Vancomycin Hydrochloride.....	304
Paclitaxel.....	270	VinBLAStine Sulfate.....	306
Pantoprazole Sodium	272	VinCRISStine Sulfate	307
Peginterferon alfa-2a	273	Vinorelbine Tartrate	309
Pemetrexed Disodium	274	Voriconazole	310
Penicillin G Potassium	275	Ziconotide Acetate.....	311
Penicillin G Sodium	277	Zidovudine	313
Pentamidine Isethionate	278	Zoledronic Acid	314
Piperacillin Sodium–Tazobactam Sodium	280		
Prochlorperazine	282		
Quinupristin–Dalfopristin	283	Part III	
Ranitidine Hydrochloride.....	284	Appendix A: Manufacturer and Compendium Abbreviations	317
Rituximab.....	286	Appendix B: Glossary of Terms.....	321
Ropivacaine Hydrochloride.....	287	Index	323
Sargramostim.....	289		



Preface

EXTENDED STABILITY FOR PARENTERAL DRUGS

The scarcity of published and/or labeled stability data beyond 24 hours at any temperature has been a historically complicating factor in the care of patients in the alternate care site. When home infusion practice emerged and grew in the 1980–90s, accurate information on extended parenteral stability was very limited. Independent and hospital-based home care pharmacists were challenged to find drug stability data that supported realistic and cost-effective compounding and patient delivery schedules. Some national infusion companies put considerable resources to the task of compiling drug stability information to support their operational and patient care processes and maintained full-time drug-information specialists supporting clinicians at their many national locations. The highly competitive nature of the home infusion industry also led to the development of unpublished, proprietary drug stability data based on independent studies contracted by large home infusion companies and drug product manufacturers.

The home infusion industry experienced tremendous change in the later part of the 1990s. Many formerly competing industry leaders merged or were acquired, resulting in fewer but larger national companies. A new trend includes acquisitions of home and specialty infusion providers by chain pharmacy corporations, pharmacy benefit managers, and pharmacy-by-mail companies. Hospital and health-system infusion programs expanded in number, scope, and size in many areas. Growth in the subacute care component of long-term care pharmacy continues to contribute to the increased use of infusion products outside the hospital setting. Free-standing, hospital-based, and physician-office-based ambulatory infusion programs have also increased in number and scope of services. Reduced reimbursement, increased case management, and changes in technology have reduced the typical length of service for alternate site infusion services from primarily long-term (months to years) parenteral nutrition therapy to include much more short-term (days to weeks) drug therapies such as anti-infectives. Inpatient pharmacy services increasingly rely on extended beyond-use dating to minimize the wastage of high cost parenteral medication via appropriate recycling of unused compounded sterile parenterals. Implementation of sterile compounding practices under USP <797> and other strict standards help to support extending beyond-use dating for many medications past the more traditional 24-hour post-admixture expiration date.

The extended stability monographs and parenteral nutrition monographs in this edition represent a continuing drug information project focused on identifying, reviewing, and compiling relevant available information in a concise format. Monographs selected include most of the anti-infective medications and other parenterals with useful extended stability dating. They cite the majority of extended stability data available at the time of the edition. Many of the monographs reference well-known sources, such as the *Handbook on Injectable Drugs* (a “must-have” reference for every pharmacy that compounds sterile preparations). Additional references and sources include previously unpublished data for specific types of infusion devices and containers, direct communications from drug and device manufacturers, and a focused review of previously published data from the perspective of practitioners who use this information in home and specialty infusion. The third edition included a comprehensive chapter on total parenteral nutrition; this chapter was reformatted for the fourth edition with stability and compatibility data summarized in parenteral nutrition monographs for some of the most common additives to parenteral nutrition preparations.

The practices and integrity of pharmacists and others who compound sterile preparations have been under great scrutiny in recent years. Increased awareness in the lay public, boards of pharmacy, and Federal regulators further presses us to employ the diligence and professionalism with which we are entrusted to protect the public. We strongly emphasize the importance of using the extended stability data in this compilation responsibly and as part of the overall quality and standards-focused process of preparing sterile compounds.

Preface

EXTENDED STABILITY FOR PARENTERAL DRUGS

The monographs and chapters are compiled as an easy-to-use reference on extended stability of the parenteral drugs and biologicals most common to alternate site infusion practice, including data in container types commonly used outside the acute care setting. Opportunities to obtain, review, and share unpublished or proprietary data will continue. Future editions will incorporate these data as they become available. We welcome your suggestions and pledge to review all resource material made available for future editions of this compendium.

What's New in This Edition

The 160 stability monographs in this fifth edition include updates to all but five of the monographs from the fourth edition, and 10 new stability monographs: Acetaminophen, Ceftriaxone, Fosamyl, Coagulation Factor XIII, Doripenem, Ethanol lock, Ibuprofen, Pantoprazole, Telavancin, Tocilizumab, and Ziconotide acetate. The monograph updates include data revisions for a number of container types, and new information for elastomeric infusion device brands. The Parenteral Nutrition chapter includes updates to five nutrition monographs and additional considerations for calcium and phosphate solubility. The Applying Stability Data in Patient Care now includes a nursing perspective, with a primer on the types of vascular access devices used in medication administration and important considerations for pH, osmolality, concentration, and administration device. Something else is new . . . a co-editor! My long time friend and colleague Anna Nowobilski-Vasilios has been a monograph writer/reviewer since the first edition of this book over a decade ago. Her contribution as a writer and now co-editor to this edition has been invaluable. As with prior editions, the publisher, editors, and writers welcome your feedback and suggestions for continued improvement.

Caryn Dellamorte Bing, April 2013
Las Vegas, NV

About the Editors

EXTENDED STABILITY FOR PARENTERAL DRUGS

Caryn Dellamorte Bing, RPh, MS, FASHP

Caryn is Senior Manager Clinical Services and PGY1 Residency Program Director for Critical Care Systems (CCS), Inc., a national home and specialty infusion provider. Her corporate responsibilities at CCS have included development of clinical standards of practice, clinician training and professional development, and leadership and management of CCS PGY1 Pharmacy Residency program at five locations. Caryn's 30-year career includes corporate leadership, general management, operations, clinical management, accreditation surveyor, consulting, training, and pharmacy practice roles in home/specialty infusion and other alternate site and acute care practice settings. Caryn holds a BS from University of Illinois College of Pharmacy and MS in Health Systems Management from Rush University. She completed her pharmacy residency at Rush-Presbyterian-St. Luke's Medical Center. She is a Rho Chi Scholar and Fellow of the American Society of Health-System Pharmacists. Caryn has been active in professional association leadership throughout her career, including terms as a presidential officer for the Illinois and Nevada ASHP state affiliates, and as an ASHP Delegate and Alternate Delegate numerous times. She served on the ASHP Home Care Section Executive Committee and was Chairperson for the ASHP Continuity of Care Task Force. Caryn received the first Distinguished Service Award from the ASHP Home Care Section. She served on editorial boards for *AJHP*, the *Journal of Pharmacy Practice*, and *Perspectives in Pharmacy*; has published a number of articles and book chapters; and has presented at many state and national meetings. Caryn has been Editor of *Extended Stability for Parenteral Drugs* since its inception.

Anna Nowobilski-Vasilios, PharmD, MBA, FASHP, CNSC, BCNSP

Anna is Principal at Anovation, Inc.; a Surveyor for the Accreditation Commission for Health Care; and Adjunct Assistant Professor at Midwestern University. Her experience includes over 30 years in pharmacy and over 25 years in home infusion and specialty pharmacy services. She served Option Care for 14 years as Senior Vice President for Care Management Services, Residency Director, Continuing Education Administrator, Vice President of Clinical Services, Senior Director of Program Development, National Director of Pharmacy, and Director of Franchise Implementation. She also held management and clinical positions with other regional and national home infusion providers and in hospital pharmacy practice. Anna holds a BS in Pharmacy from the University of Illinois, a MBA from Keller Graduate School of Management, and a PharmD from Midwestern University. She is a Rho Chi Scholar, board certified in nutrition support as well as nutrition support pharmacy, and a Fellow of the American Society of Health-System Pharmacists; she has served as Director-At-Large for ASHP's Section of Ambulatory Care Practitioners. She is an active member in the National Home Infusion Association, American Society of Health-System Pharmacists, American Society for Parenteral and Enteral Nutrition, Infusion Nurses Society, the Illinois Council of Health-System Pharmacists, and the Polish American Pharmacists' Association. Anna has delivered numerous presentations and has published articles on the subjects of home infusion therapy, specialty pharmacy, nutrition support, new drug approvals, and interdisciplinary collaboration. She is the author of the Home Infusion Chapter in the 22nd edition of *Remington: The Science and Practice of Pharmacy* and has been a contributing writer to each edition of *Extended Stability for Parenteral Drugs*.

Writers

EXTENDED STABILITY FOR PARENTERAL DRUGS

Caryn Dellamorte Bing, RPh, MS, FASHP

Senior Manager, Clinical Services
PGY1 Residency Program Director
Critical Care Systems, Inc.
and
President
CB Healthcare Consulting
Las Vegas, Nevada

Donald J. Filibeck, PharmD, MBA

Dublin, Ohio

Brenda L. Gray, PharmD, CNSC, BCNSP

Tampa, Florida

J. Michael Hayes, PharmD, CPh

Drug Information Coordinator/Investigational
Pharmacy Team Lead
Moffitt Cancer Center
Department of Pharmacy
Tampa, Florida

Barbara Limburg-Mancini, PharmD, BCNSP

Director of Pharmacy
Walgreens Specialty Infusion Pharmacy
Lombard, Illinois

Kevn M. McNamara, PharmD, CNSC

National Director of Clinical Pharmacy
Operations
BioScrip Inc.
Tampa, Florida

Diane Nitzki-George, PharmD, MBA

Clinical Pharmacist
NorthShore University Health System
Pharmacy Services
Evanston, Illinois
and
Clinical Assistant Professor
Working Professional Doctor of Pharmacy
Program
University of Florida College of Pharmacy

**Anna Nowobilski-Vasilios, PharmD, MBA,
FASHP, CNSC, BCNSP**

Principal
Anovation, Care Management Innovation
Chicago, Illinois
and
Adjunct Assistant Professor, Pharmacy Practice
Midwestern University, Chicago College of
Pharmacy
Downers Grove, Illinois

Kevin L. Ross, BS, RN

Nursing Consultant
Bartonville, Texas

Lisa Linn Siefert, RPh, FASHP, ASQ-CMQ/OE

Corporate Manager, Accreditation, Quality,
and Clinical Education
Walgreens Infusion and Respiratory Services
Deerfield, Illinois

Paula Zelle, PharmD, FASHP

Health Care Consultant
Infusion Consultant Services and Accreditation
Resources
Canton, Ohio



How to Use This Reference

EXTENDED STABILITY FOR PARENTERAL DRUGS

Each monograph in this reference represents a drug for which some extended parenteral stability information is available from peer reviewed publications and/or drug and/or device/container manufacturers. Practitioners who are unfamiliar with this reference and the principles of extended stability should review the “Applying Stability Data in Patient Care” chapter. Selected monographs include shorter stability data that may be useful in alternate site practice. Stability monographs are alphabetical by generic drug name. Each monograph includes a compilation of drug stability data for various container systems, solutions, concentrations, and temperature storage and administration conditions. The parenteral nutrition additive monographs are only applicable to parenteral nutrition formulations.

The following temperature ranges were adapted from the USP to evaluate reported stability study conditions¹:

Refrigerated	2°C to 8°C
Frozen	–25°C to –10°C
Room Temperature*	15°C to 30°C
Body Temperature	37°C

*See the USP definition of Controlled Room Temperature in Appendix B, Glossary of Terms.

When studied storage conditions fall outside these ranges, a monograph note will indicate the variation.

To use a stability monograph, find the desired container or material type in the first column. When a container type is not listed, then clinically useful or extended stability data were not available for the drug in that container type. Next, check the concentration, diluent, and manufacturer of the drug studied in that container type. The next column indicates the osmolality of the sample studied if it was assayed or calculated by the authors of the cited study. The pH column either includes the actual or range of pH for the specific concentration, or a note that ties to more general pH data for the drug product. Additional columns list the extended stability data that have been documented for the drug in the container and specified conditions. If frozen stability information is available, check the post-thaw stability data; this may differ from the room temperature and refrigerated stability data for the same drug in a never-frozen state. The final column indicates the reference or references used for the particular line in the monograph. When “n/a” is noted in any field, no information is available for that item.

Within the stability monograph, footnotes highlight important information. Each footnote corresponds to information in the Notes section of the monograph that is crucial to interpretation of the data. These include comments on variations from USP temperature ranges, detailed descriptions of storage conditions, and more. A Special Considerations section includes special information on drug storage, preparation, and administration.

Flush compatibility refers to the chemical compatibility of the drug with common solutions used to flush vascular access devices. Practitioners should be aware of nursing practice guidelines (such as those of the Intravenous Nurses Society), access device specifications, and drug-solution compatibility when determining the type and volume of solution(s) used for line maintenance. When a drug is incompatible with heparinized saline (i.e., heparin lock flush), it may be necessary to flush with saline before and after administration. (Commonly referred to as SASH, this stands for Saline-Administration-Saline-Heparin.) A few drugs are not compatible with saline or heparinized saline; in these cases, flushing with an alternative compatible solution, such as D5W, may be necessary. If the line flush procedures for a specific therapy vary from the organization’s standard approach, the pharmacist should provide written directions to clarify the flush method used. Heparinization may not always be required to maintain line patency for some access devices (e.g., Groshong catheters) or when positive displacement catheter caps are used.

How to Use This Reference

EXTENDED STABILITY FOR PARENTERAL DRUGS

Use of Additional Resources

The information contained in these monographs is a compilation of extended stability data from multiple sources. This information is not a substitute for the official product literature. Practitioners should consult the primary literature and the product manufacturer to determine the applicability of stability data to a particular patient and practice scenario. Practitioners should maintain current drug reference resources as well as the most current edition of a comprehensive reference on drug stability and compatibility. Every pharmacy that compounds or provides sterile preparations should maintain resource files, including the phone numbers and all correspondence with the medical or clinical affairs departments of pharmaceutical manufacturers. The pharmacy should also have access to a drug information center or the expertise and ability to conduct a literature search for the most up-to-date clinical and pharmaceutical information on parenteral drugs.

General Abbreviations

d	day(s)
h	hour(s)
iso	iso-osmotic
m	month(s)
min	minute(s)
RTU	ready to use from manufacturer
unspec.	unspecified
w	week(s)
y	year(s)

Solution Abbreviations

BWFI	Bacteriostatic water for injection
D	Dextrose solution (percentage unspecified)
D2.5	Dextrose 2.5% in water
D2.5 ¹ / ₂ S	Dextrose 2.5% in sodium chloride 0.45%
D5LR	Dextrose 5% in lactated Ringer's
D5 ¹ / ₄ S	Dextrose 5% in sodium chloride 0.225%
D5 ¹ / ₂ S	Dextrose 5% in sodium chloride 0.45%
D5S	Dextrose 5% in sodium chloride 0.9%
D10S	Dextrose 10% in sodium chloride 0.9%
D5W	Dextrose 5% in water
D7W	Dextrose 7% in water
D10W	Dextrose 10% in water
DXN-6	Dextran 6%
LR	Ringer's injection, lactated
M10	Mannitol 10%
NS	Sodium chloride 0.9%
R	Ringer's solution
¹ / ₂ S	Sodium chloride 0.45%
¹ / ₄ S	Sodium chloride 0.22%
W	Sterile water for injection

Reference

1. United States Pharmacopeial Convention. Chapter <795> Pharmaceutical Compounding—Nonsterile Preparations. Official August 1, 2008.